Forest has well-established franchises in the therapeutic areas of the central nervous and cardiovascular systems, and we are always exploring new product opportunities that address a range of health conditions. Our principal brands include Bystolic® (nebivolol), Daliresp™ (roflumilast), Lexapro® (escitalopram oxalate), Namenda® (memantine HCl), Savella®(milnacipran HCl), Teflaro™ (ceftaroline fosamil) for injection, and Viibryd™ (vilazodone HCl). Forest identifies, develops, and delivers pharmaceutical products that make a difference in people's lives.